WATERTOWN, Mass., April 8, 2026
Dyno Therapeutics, Inc. has announced that Astellas Pharma has exercised its option to license a novel AI-designed adeno-associated virus (AAV) capsid for targeted gene delivery to skeletal muscle, marking a major milestone in the application of artificial intelligence to gene therapy development. The agreement includes a $15 million upfront license fee along with potential milestone and royalty payments, underscoring strong industry validation of Dyno’s AI-powered biological sequence design platform.
AI-Engineered Capsids Advance Gene Therapy Delivery
The licensed capsid represents a next-generation gene delivery vector engineered using artificial intelligence trained on billions of in vivo data points, enabling precise optimization beyond traditional approaches such as rational design or directed evolution. This innovation addresses a long-standing limitation in gene therapy, where conventional AAV capsids require high doses to effectively target skeletal muscle, leading to increased safety risks and manufacturing challenges.
Dyno’s AI-designed capsid demonstrates enhanced skeletal muscle targeting at significantly lower doses, improving both therapeutic safety and efficiency. Preclinical studies in nonhuman primates have shown superior delivery performance, positioning the capsid as a promising candidate for further development in muscle-related genetic diseases. Importantly, the capsid is compatible with existing AAV9-based manufacturing processes, enabling scalable production and facilitating its transition toward clinical applications.
Strategic Collaboration Validates AI-Driven Platform
Advertisement
The licensing agreement builds on a 2021 research collaboration between Dyno Therapeutics and Astellas Pharma, marking the first muscle-targeted capsid licensed under this partnership. This milestone also represents Dyno’s second successful capsid licensing, following a previous agreement with Roche for a central nervous system (CNS)-targeted gene therapy vector.
Astellas will assume responsibility for preclinical development, clinical trials, and commercialization activities, highlighting confidence in the capsid’s potential to support future therapeutic programs. The agreement further validates Dyno’s position as the first company to successfully license AI-designed AAV capsids across both CNS and muscle gene therapy applications, demonstrating the versatility and scalability of its technology platform.
This collaboration reflects a broader industry trend toward integrating artificial intelligence into drug discovery and development, where advanced computational models enable faster and more efficient design of complex biological systems. By leveraging AI, Dyno is able to navigate vast sequence spaces and identify optimized capsid variants with unprecedented speed and precision, significantly accelerating innovation in gene therapy.
Transforming the Future of Genetic Medicine
Gene therapy has emerged as a transformative approach for treating genetic disorders by addressing the root cause of disease, but its success depends heavily on the ability to deliver therapeutic genes safely and efficiently to target tissues. Dyno’s AI-powered platform aims to overcome these challenges by creating high-performance genetic delivery systems that expand the possibilities of precision medicine.
The newly licensed capsid is expected to play a critical role in advancing therapies for muscle-related genetic conditions, where effective delivery has historically been difficult to achieve. By enabling lower-dose administration and improved targeting, the technology has the potential to reduce adverse effects while enhancing therapeutic outcomes.
Dyno continues to expand its portfolio of AI-designed capsids for multiple therapeutic areas, including ocular, neurological, and muscular diseases. Through strategic partnerships with leading biopharmaceutical companies and technology innovators, the company is advancing its mission to make gene therapies safer, more effective, and widely accessible.
The licensing of Dyno’s AI-designed AAV capsid by Astellas marks a significant breakthrough in gene therapy innovation, demonstrating the power of artificial intelligence in solving complex biological challenges. With its ability to improve targeting precision, safety, and scalability, this technology represents a critical step toward the next generation of genetic medicines, reinforcing the growing role of AI in transforming the future of healthcare.
Source: Dyno Therapeutics press release
